Board meeting outcome
Awaiting price reaction for this filing.
Dolphin Medical Services posted weak Q2 FY26 results, with revenue from operations falling sharply to Rs. 18.34 lakhs versus Rs. 25.24 lakhs in Q2 FY25 (a ~27% year-on-year decline). For the six months ended September 2025, total revenue slipped to Rs. 37.04 lakhs from Rs. 41.13 lakhs a year earlier. Despite the revenue drop, half-yearly net profit rose ~26% to Rs. 3.73 lakhs from Rs. 2.97 lakhs, helped by lower employee and other expenses. Q2 standalone profit, however, fell to just Rs. 0.60 lakhs (vs Rs. 1.94 lakhs). The company's reserves remain deeply negative at Rs. (502.31) lakhs, and it reported a negative operating cash flow of Rs. (7.29) lakhs for the half-year. The auditor issued a clean limited review report with no qualifications.
Mixed picture for shareholders: cost discipline boosted half-yearly profits, but shrinking top line and continuing negative reserves suggest underlying business weakness. The negative operating cash flow and already eroded equity base are concerns that could weigh on sentiment for this micro-cap stock.